| 7.26 0.14 (1.97%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.43 | 1-year : | 10.51 |
| Resists | First : | 8.07 | Second : | 9 |
| Pivot price | 7.23  |
|||
| Supports | First : | 6.57 | Second : | 5.47 |
| MAs | MA(5) : | 6.95  |
MA(20) : | 7.39 |
| MA(100) : | 6.35 |
MA(250) : | 4.29 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 22.2 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 9 | Low : | 1.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TCRX ] has closed above bottom band by 44.1%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.25 - 7.3 | 7.3 - 7.34 |
| Low: | 6.65 - 6.7 | 6.7 - 6.74 |
| Close: | 7.05 - 7.13 | 7.13 - 7.2 |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Tue, 23 Apr 2024
Unveiling 4 Analyst Insights On TScan Therapeutics - TScan Therapeutics (NASDAQ:TCRX) - Benzinga
Mon, 22 Apr 2024
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th ... - Yahoo Canada Finance
Fri, 19 Apr 2024
Q1 2024 EPS Estimates for TScan Therapeutics, Inc. (NASDAQ:TCRX) Reduced by Analyst - MarketBeat
Fri, 19 Apr 2024
TScan Therapeutics Announces Closing of Upsized Public Offering - GlobeNewswire
Thu, 18 Apr 2024
Wedbush Weighs in on TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX) - MarketBeat
Tue, 16 Apr 2024
TScan Therapeutics Advances in Solid and Hematological Cancer Therapy - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 83.1 (%) |
| Shares Short | 219 (K) |
| Shares Short P.Month | 188 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.15 |
| Profit Margin | 0 % |
| Operating Margin | -296.2 % |
| Return on Assets (ttm) | -24.8 % |
| Return on Equity (ttm) | -71.3 % |
| Qtrly Rev. Growth | 133 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.45 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -5.27 |
| PEG Ratio | 0 |
| Price to Book value | 2.27 |
| Price to Sales | 15.68 |
| Price to Cash Flow | -5.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|